Biotech

All Articles

AN 2 halves headcount, ceases stage 3 test after information disappoint

.AN2 Rehabs is actually rethinking its business in reaction to dull midphase information, pledging t...

Merck pays out $700M for bispecific, snooping autoimmune position and opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually paying out $700 thousand ahead of time to test Amgen in a blood cancer c...

Gilead pays for J&ampJ $320M to exit licensing offer for seladelpar

.Along With Gilead Sciences on the verge of an FDA decision for its liver illness medicine seladelpa...

' All hands on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks may find the firms establishing camping tents at basecamp behin...

Entero giving up team, vacating workplace and stopping R&ampD

.Bed mattress Liquidators has switched Entero Rehabs white colored as a piece. The creditor purchase...

Exelixis loses ADC after determining it's no match for Tivdak

.Exelixis is quiting on its own cells factor (TF)- targeting antibody-drug conjugate after wrapping ...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.3 full weeks after Roche's Genentech device bowed out an SHP2 prevention deal, Relay Therapy has ve...

Stoke's Dravet syndrome med released of predisposed scientific grip

.Stoke Rehabs' Dravet disorder drug has actually been actually devoid of a partial grip, removing th...

Fierce Biotech's Gabrielle Masson offers Brutal 15 at NYSE

.Ferocious Biotech Associate Publisher Gabrielle Masson presented the 2024 lesson of Brutal 15 champ...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH prospect

.Novo Nordisk has axed its own once-monthly double GLP-1/ GIP receptor agonist, finishing (PDF) deve...